Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma

被引：0
|
作者：
S Lee
Y H Park
K H Kim
E Y Cho
Y C Ahn
K Kim
Y-M Shim
J S Ahn
K Park
Y-H Im
机构：
[1] Samsung Medical Center,Division of Hematology
[2] Sungkyunkwan University School of Medicine,Oncology, Department of Medicine
[3] Samsung Medical Center,Department of Pathology
[4] Sungkyunkwan University School of Medicine,Department of Radiation Oncology
[5] Samsung Medical Center,Department of Thoracic Surgery
[6] Sungkyunkwan University School of Medicine,undefined
[7] Samsung Medical Center,undefined
[8] Sungkyunkwan University School of Medicine,undefined
来源：
British Journal of Cancer | 2010年 / 103卷
关键词：
oesophageal cancer; capecitabine; cisplatin; thymidine synthase (TS); thymidine phosphorylase (TP); excesion repair cross-complementation group 1 (ERCC1);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：845 / 851
页数：6
相关论文
共 15 条
  • [1] Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma
    Lee, S.
    Park, Y. H.
    Kim, K. H.
    Cho, E. Y.
    Ahn, Y. C.
    Kim, K.
    Shim, Y-M
    Ahn, J. S.
    Park, K.
    Im, Y-H
    BRITISH JOURNAL OF CANCER, 2010, 103 (06) : 845 - 851
  • [2] Expressions of Thymidylate Synthase, Thymidine Phosphorylase, Class Ⅲ β-tubulin, and Excision Repair Cross-complementing Group 1 Predict Response in Advanced Gastric Cancer Patients Receiving Capecitabine Plus Paclitaxel or Cisplatin
    Ming Lu
    Chinese Journal of Cancer Research, 2011, 23 (04) : 288 - 294
  • [3] Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy
    Kim, Kyoung Ha
    Do, In-Gu
    Kim, Hyeong Su
    Chang, Myung Hee
    Kim, Hyo Song
    Jun, Hyun Jung
    Uhm, Jieun
    Yi, Seong Yoon
    Lim, Do Hyoung
    Ji, Sang Hoon
    Park, Min Jae
    Lee, Jeeyun
    Park, Se Hoon
    Kwon, Ghee Young
    Lim, Ho Yeong
    APMIS, 2010, 118 (12) : 941 - 948
  • [4] Expression of excision repair cross-complementation group 1 in locoregionally advanced nasopharyngeal carcinoma treated with cisplatin-based induction chemotherapy
    Shen, Chuan
    Chen, Lingling
    Fu, Jiangtao
    Lin, Hongbin
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (05) : 72 - 75
  • [5] Expressions of thymidylate synthase, thymidine phosphorylase, class III β-tubulin, and excision repair cross-complementing group 1 predict response in advanced gastric cancer patients receiving capecitabine plus paclitaxel or cisplatin
    Lu, Ming
    Gao, Jing
    Wang, Xi-cheng
    Shen, Lin
    CHINESE JOURNAL OF CANCER RESEARCH, 2011, 23 (04) : 288 - 294
  • [6] Predictive and Prognostic Value of Ribonucleotide Reductase Regulatory Subunit M1 and Excision Repair Cross-Complementation Group 1 in Advanced Urothelial Carcinoma (UC) Treated with First-Line Gemcitabine Plus Platinum Combination Chemotherapy
    Kim, Miso
    Ku, Ja Hyeon
    Kwak, Cheol
    Kim, Hyeon Hoe
    Lee, Eunsik
    Keam, Bhumsuk
    Kim, Tae Min
    Heo, Dae Seog
    Lee, Se-Hoon
    Moon, Kyung Chul
    PLOS ONE, 2015, 10 (07):
  • [7] A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma
    Jeeyun Lee
    Young-Hyuck Im
    Eun Yoon Cho
    Yong Sang Hong
    Hyo Rak Lee
    Hyo Song Kim
    Mi-Jin Kim
    Kwhanmien Kim
    Won Ki Kang
    Keunchil Park
    Young Mog Shim
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 77 - 84
  • [8] Is there relationship between excision repair cross-complementation 1 expression level and response to treatment and prognosis in an advanced stage lung cancer treated with cisplatin-based chemotherapy?
    Polat, G.
    Yilmaz, U.
    Anar, C.
    Komurcuoglu, B.
    Aydogdu, Z.
    INDIAN JOURNAL OF CANCER, 2015, 52 (03) : 277 - U295
  • [9] Thymidylate Synthase But Not Excision Repair Cross-Complementation Group 1 Tumor Expression Predicts Outcome in Patients With Malignant Pleural Mesothelioma Treated With Pemetrexed-Based Chemotherapy
    Righi, Luisella
    Papotti, Mauro G.
    Ceppi, Paolo
    Bille, Andrea
    Bacillo, Elisa
    Molinaro, Luca
    Ruffini, Enrico
    Scagliotti, Giorgio V.
    Selvaggi, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) : 1534 - 1539
  • [10] A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma
    Wang, Hai-ying
    Yao, Zhi-hua
    Tang, Hong
    Zhao, Yan
    Jin, Shui-ling
    Zhou, Wen-ping
    Yao, Shu-na
    Yang, Shu-jun
    Liu, Yan-yan
    Luo, Su-xia
    ONCOTARGET, 2017, 8 (05) : 7540 - 7547
12